Skip to main content
Fig. 4 | BMC Immunology

Fig. 4

From: Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV

Fig. 4

Estimated VRC07-523LS serum concentrations over time via the base popPK model. Red line and purple shaded area represent the median and 95% empirical confidence interval, respectively, of simulated concentrations after intravenous administration of VRC07-523LS alone at 1.4 g. Blue line and blue shaded area represent the median and 95% empirical confidence interval, respectively, of simulated concentrations after an IV administration of VRC07-523LS at 1.4 g co-administered with other mAbs. PK parameter estimate values from the base popPK model were used in these simulations, with the dose level of 1.4g being equivalent to 20 mg/kg for a 70kg person

Back to article page